By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Meridian Bioscience today provided guidance for its 2012 fiscal year, projecting net income to improve between 20 and 30 percent above projected fiscal 2011 income on the strength of its illumigene franchise.

For the year ending Sept. 30, 2012, the company expects EPS to fall between $.85 and $.89 on net sales of between $183 million and $192 million. The guidance excludes reorganization costs in 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.